Viridian Therapeutics, Inc. (0K1R.L)
USD 19.62
(-7.91%)
USD 19.62
(-7.91%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 254.76 Million USD | 87.22% |
| 2022 | 136.07 Million USD | 64.56% |
| 2021 | 82.69 Million USD | 98.92% |
| 2020 | 41.56 Million USD | -10.49% |
| 2019 | 46.44 Million USD | 11.98% |
| 2018 | 41.47 Million USD | 35.81% |
| 2017 | 30.53 Million USD | 191.84% |
| 2016 | 10.46 Million USD | -7.02% |
| 2015 | 11.25 Million USD | 39.89% |
| 2014 | 8.04 Million USD | 255.34% |
| 2013 | 2.26 Million USD | -49.23% |
| 2012 | 4.45 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 55.96 Million USD | -21.78% |
| 2024 Q2 | 72.25 Million USD | 29.11% |
| 2023 Q2 | 59.34 Million USD | -18.22% |
| 2023 FY | 254.76 Million USD | 87.22% |
| 2023 Q3 | 51.29 Million USD | -13.57% |
| 2023 Q4 | 71.55 Million USD | 39.48% |
| 2023 Q1 | 72.57 Million USD | 47.59% |
| 2022 Q4 | 49.17 Million USD | 58.72% |
| 2022 Q2 | 29.82 Million USD | 14.23% |
| 2022 Q1 | 26.1 Million USD | -10.89% |
| 2022 FY | 136.07 Million USD | 64.56% |
| 2022 Q3 | 30.98 Million USD | 3.89% |
| 2021 Q2 | 19.08 Million USD | -4.4% |
| 2021 Q4 | 29.29 Million USD | 104.26% |
| 2021 FY | 82.69 Million USD | 98.92% |
| 2021 Q1 | 19.96 Million USD | -3.97% |
| 2021 Q3 | 14.34 Million USD | -24.86% |
| 2020 Q2 | 6.54 Million USD | -25.88% |
| 2020 Q3 | 5.41 Million USD | -17.3% |
| 2020 FY | 41.56 Million USD | -10.49% |
| 2020 Q4 | 20.79 Million USD | 284.31% |
| 2020 Q1 | 8.82 Million USD | -19.4% |
| 2019 Q3 | 11.92 Million USD | 4.09% |
| 2019 Q1 | 12.1 Million USD | 10.79% |
| 2019 FY | 46.44 Million USD | 11.98% |
| 2019 Q4 | 10.95 Million USD | -8.17% |
| 2019 Q2 | 11.45 Million USD | -5.38% |
| 2018 FY | 41.47 Million USD | 35.81% |
| 2018 Q4 | 10.92 Million USD | 8.26% |
| 2018 Q3 | 10.09 Million USD | -8.58% |
| 2018 Q2 | 11.04 Million USD | 17.44% |
| 2018 Q1 | 9.4 Million USD | 24.61% |
| 2017 Q1 | 7.4 Million USD | 173.81% |
| 2017 Q2 | 8.06 Million USD | 9.01% |
| 2017 Q3 | 7.52 Million USD | -6.79% |
| 2017 Q4 | 7.54 Million USD | 0.35% |
| 2017 FY | 30.53 Million USD | 191.84% |
| 2016 FY | 10.46 Million USD | -7.02% |
| 2016 Q1 | 2.92 Million USD | -7.47% |
| 2016 Q2 | 2.73 Million USD | -6.63% |
| 2016 Q3 | 2.1 Million USD | -22.86% |
| 2016 Q4 | 2.7 Million USD | 28.35% |
| 2015 FY | 11.25 Million USD | 39.89% |
| 2015 Q4 | 3.16 Million USD | 3.54% |
| 2015 Q2 | 2.54 Million USD | 1.96% |
| 2015 Q1 | 2.49 Million USD | 18.87% |
| 2015 Q3 | 3.05 Million USD | 19.87% |
| 2014 Q4 | 2.1 Million USD | 1.85% |
| 2014 FY | 8.04 Million USD | 255.34% |
| 2014 Q1 | 594.1 Thousand USD | -14.75% |
| 2014 Q2 | 3.4 Million USD | 473.85% |
| 2014 Q3 | 2.06 Million USD | -39.5% |
| 2013 Q1 | 549.67 Thousand USD | 0.0% |
| 2013 FY | 2.26 Million USD | -49.23% |
| 2013 Q4 | 696.91 Thousand USD | 19.73% |
| 2013 Q3 | 582.04 Thousand USD | 3.9% |
| 2013 Q2 | 560.22 Thousand USD | 1.92% |
| 2012 FY | 4.45 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -51.253% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 42.844% |
| Codexis, Inc. | 66.51 Million USD | -283.0% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1608.106% |